BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26121460)

  • 1. BASAL-BOLUS REGIMEN WITH INSULIN ANALOGUES VERSUS HUMAN INSULIN IN MEDICAL PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CONTROLLED TRIAL IN LATIN AMERICA.
    Bueno E; Benitez A; Rufinelli JV; Figueredo R; Alsina S; Ojeda A; Samudio S; Cáceres M; Argüello R; Romero F; Echagüe G; Pasquel F; Umpierrez GE
    Endocr Pract; 2015 Jul; 21(7):807-13. PubMed ID: 26121460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.
    Bellido V; Suarez L; Rodriguez MG; Sanchez C; Dieguez M; Riestra M; Casal F; Delgado E; Menendez E; Umpierrez GE
    Diabetes Care; 2015 Dec; 38(12):2211-6. PubMed ID: 26459273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
    Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial.
    Umpierrez GE; Smiley D; Hermayer K; Khan A; Olson DE; Newton C; Jacobs S; Rizzo M; Peng L; Reyes D; Pinzon I; Fereira ME; Hunt V; Gore A; Toyoshima MT; Fonseca VA
    Diabetes Care; 2013 Aug; 36(8):2169-74. PubMed ID: 23435159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMPARISON OF BASAL INSULIN REGIMENS ON GLYCEMIC VARIABILITY IN NONCRITICALLY ILL PATIENTS WITH TYPE 2 DIABETES.
    Haw JS; Farrokhi F; Smiley D; Peng L; Reyes D; Newton C; Pasquel FJ; Vellanki P; Umpierrez GE
    Endocr Pract; 2015 Dec; 21(12):1333-43. PubMed ID: 26307899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
    Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
    Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).
    Umpierrez GE; Smiley D; Jacobs S; Peng L; Temponi A; Mulligan P; Umpierrez D; Newton C; Olson D; Rizzo M
    Diabetes Care; 2011 Feb; 34(2):256-61. PubMed ID: 21228246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).
    Umpierrez GE; Smiley D; Zisman A; Prieto LM; Palacio A; Ceron M; Puig A; Mejia R
    Diabetes Care; 2007 Sep; 30(9):2181-6. PubMed ID: 17513708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study.
    Vellanki P; Cardona S; Galindo RJ; Urrutia MA; Pasquel FJ; Davis GM; Fayfman M; Migdal A; Peng L; Umpierrez GE
    Diabetes Care; 2022 Oct; 45(10):2217-2223. PubMed ID: 35675498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial.
    Umpierrez GE; Jones S; Smiley D; Mulligan P; Keyler T; Temponi A; Semakula C; Umpierrez D; Peng L; Cerón M; Robalino G
    Diabetes Care; 2009 Jul; 32(7):1164-9. PubMed ID: 19366972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes.
    Farrokhi F; Klindukhova O; Chandra P; Peng L; Smiley D; Newton C; Pasquel F; Fereira ME; Umpierrez G
    J Diabetes Sci Technol; 2012 Sep; 6(5):1022-9. PubMed ID: 23063027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
    Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
    Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
    Yeldandi RR; Lurie A; Baldwin D
    Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.